0001104659-24-060517.txt : 20240513 0001104659-24-060517.hdr.sgml : 20240513 20240513160533 ACCESSION NUMBER: 0001104659-24-060517 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240513 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 24938987 BUSINESS ADDRESS: STREET 1: 111 S. WOOD AVENUE STREET 2: UNIT #100 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 111 S. WOOD AVENUE STREET 2: UNIT #100 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 8-K 1 tm2414311d1_8k.htm FORM 8-K
false 0001649989 0001649989 2024-05-13 2024-05-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2024

 

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-37759 38-3982704
(State or other jurisdiction
of incorporation) 		(Commission File Number) (IRS Employer Identification No.)

 

111 S. Wood Avenue, Unit #100

Iselin, New Jersey

 08830
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (609) 619-3990

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which
Registered
Common Stock   OTLK   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01 Other Events.

 

On May 13, 2024, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing the submission of its Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom seeking authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma ) for the treatment of wet age-related macular degeneration. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

 

Item 9.01Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press release, dated May 13, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Outlook Therapeutics, Inc.
   
Date: May 13, 2024 By: /s/ Lawrence A. Kenyon
    Lawrence A. Kenyon
    Chief Financial Officer

 

 

 

 EX-99.1 2 tm2414311d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

 

·UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma)

 

ISELIN, N.J., May 13, 2024 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and Europe, today announced the submission of its Marketing Authorization Application (MAA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) seeking authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD).

 

The submission was completed under the new International Recognition Procedure (IRP), which allows the MHRA to rely on a positive opinion by the European Medicines Agency’s CHMP concerning an application for grant of marketing authorization for the same product in the EU. The IRP is available for new UK MAAs of a medicinal product (having the same qualitative and quantitative composition, and the same pharmaceutical form) that has previously been authorized by a Reference Regulator (RR). In this case this is the EMA.

 

“The submission of our MAA to the MHRA is another step closer to the possibility of offering clinicians and their patients in the UK market the only on-label, ophthalmic bevacizumab to treat wet AMD,” said Russell Trenary, President and CEO of Outlook Therapeutics. “On the heels of the recent positive opinion by the CHMP in the EU, we continue to make noteworthy progress toward the potential authorization of ONS-5010/LYTENAVA™ in the UK.”

 

The MAA submission is supported by results from Outlook Therapeutics’ wet AMD clinical program for ONS-5010, which consists of three completed registration clinical trials - NORSE ONE, NORSE TWO and NORSE THREE.

 

As previously announced, Outlook Therapeutics received a CHMP positive opinion on March 22, 2024 concerning an application for grant of marketing authorization for ONS-5010/LYTENAVA™ in the EU. The European Commission is expected to make a decision within approximately 67 days following the CHMP opinion. The decision will apply automatically in all 27 EU Member States, and, within 30 days, also to Iceland, Norway and Liechtenstein.

 

 

 

 

About ONS-5010 / LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)

 

ONS-5010/LYTENAVA™ is an investigational ophthalmic formulation of bevacizumab under development as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Because no FDA or European Commission approved ophthalmic formulations of bevacizumab are currently available, clinicians wishing to treat retinal patients with bevacizumab have had to use repackaged IV bevacizumab authorized for a different therapeutic indication and provided by compounding pharmacies—products that have known risks of contamination and inconsistent potency and availability. If approved, ONS-5010/LYTENAVA™ would provide an authorized option for physicians to treat wet AMD in the United States, EU and the UK.

 

Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.

 

About Outlook Therapeutics, Inc.

 

Outlook Therapeutics is a biopharmaceutical company working to achieve FDA, European Commission and MHRA approval for the launch of ONS-5010/LYTENAVA™ (bevacizumab-vikg or bevacizumab gamma) as the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010/Lytenava™ is approved, Outlook Therapeutics expects to commercialize it as the first and only European Commission, MHRA or FDA approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, EU, and UK. Authorization may also be sought in other European markets, Japan, and other markets. As part of the Outlook Therapeutics multi-year commercial planning process, Outlook Therapeutics and Cencora have entered into a strategic commercialization agreement to expand Outlook Therapeutics’ reach for connecting to retina specialists and their patients. Cencora will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services and other services in the United States, EU and UK.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “continue,” “expect,” “may,” “plan,” “possible,” “potential,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, ONS-5010’s potential as the only on-label, ophthalmic bevacizumab to treat wet AMD for patients and clinicians in the UK market, expectations concerning decisions of regulatory bodies, including the European Commission and the MHRA, and the timing thereof, expectations concerning the relationship with Cencora and the benefits and potential expansion thereof, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by the FDA, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2023, filed with the SEC on December 22, 2023, and future quarterly reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, high interest rates, inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

 

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com

 

# #

 

 

 

 EX-101.SCH 3 otlk-20240513.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 otlk-20240513_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 otlk-20240513_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2414311d1_ex99-1img01.jpg GRAPHIC begin 644 tm2414311d1_ex99-1img01.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 13, 2024
Entity File Number 001-37759
Entity Registrant Name Outlook Therapeutics, Inc.
Entity Central Index Key 0001649989
Entity Tax Identification Number 38-3982704
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 111 S. Wood Avenue
Entity Address, Address Line Two Unit #100
Entity Address, City or Town Iselin
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08830
City Area Code 609
Local Phone Number 619-3990
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OTLK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://outlooktherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports otlk-20240513.xsd otlk-20240513_lab.xml otlk-20240513_pre.xml tm2414311d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2414311d1_8k.htm": { "nsprefix": "otlk", "nsuri": "http://outlooktherapeutics.com/20240513", "dts": { "schema": { "local": [ "otlk-20240513.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "otlk-20240513_lab.xml" ] }, "presentationLink": { "local": [ "otlk-20240513_pre.xml" ] }, "inline": { "local": [ "tm2414311d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://outlooktherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414311d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414311d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-060517-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-060517-xbrl.zip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end XML 18 tm2414311d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001649989 2024-05-13 2024-05-13 iso4217:USD shares iso4217:USD shares false 0001649989 8-K 2024-05-13 Outlook Therapeutics, Inc. DE 001-37759 38-3982704 111 S. Wood Avenue Unit #100 Iselin NJ 08830 609 619-3990 false false false false Common Stock OTLK NASDAQ false